• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Norwegian Cruise Line Posts Strong Sales, Joins Hims & Hers Health, Sterling Infrastructure And Other Big Stocks Moving Higher On Tuesday

    2/27/24 10:27:54 AM ET
    $AHCO
    $BBAI
    $BEAM
    $CEG
    Medical/Nursing Services
    Health Care
    Computer Software: Prepackaged Software
    Technology
    Get the next $AHCO alert in real time by email

    U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday.

    Shares of Norwegian Cruise Line Holdings Ltd. (NYSE:NCLH) rose sharply during Tuesday’s session following better-than-expected fourth-quarter revenues.

    Norwegian Cruise Line posted adjusted loss of 18 cents per share on revenue of $1.99 billion, according to data from Benzinga Pro.

    Norwegian Cruise Line shares jumped 13% to $18.00 on Tuesday.

    Here are some other big stocks recording gains in today’s session.

    • Janux Therapeutics, Inc. (NASDAQ:JANX) shares rose 145% to $37.00 after the company announced updated clinical data for both of its clinical programs.
    • Viking Therapeutics, Inc. (NASDAQ:VKTX) shares jumped 71.2% to $65.88 after the company announced the Phase 2 VENTURE trial successfully achieved its primary endpoint and all secondary endpoints.
    • WeTrade Group, Inc. (NASDAQ:WETG) gained 50% to $3.36.
    • Hims & Hers Health, Inc. (NYSE:HIMS) climbed 33.6% to $13.70 after the company reported better-than-expected fourth-quarter financial results and issued strong guidance.
    • AdaptHealth Corp. (NASDAQ:AHCO) jumped 29.6% to $9.89 following fourth-quarter results.
    • Beam Therapeutics Inc. (NASDAQ:BEAM) gained 26.8% to $45.43 after the company reported fourth-quarter financial results.
    • BigBear.ai Holdings, Inc. (NYSE:BBAI) rose 26% to $3.14. Cantor Fitzgerald analyst Yi Fu Lee maintained BigBear.ai with an Overweight and maintained $3 price target.
    • Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) gained 23% to $91.68 following upbeat quarterly earnings.
    • SoundHound AI, Inc. (NASDAQ:SOUN) jumped 22.3% to $7.03 after gaining more than 46% on Monday.
    • PubMatic, Inc. (NASDAQ:PUBM) shares climbed 20.8% to $20.01 after the company reported better-than-expected fourth-quarter financial results and issued strong guidance.
    • Sterling Infrastructure, Inc. (NASDAQ:STRL) jumped 19% to $107.00 after the company reported fourth-quarter financial results.
    • Denali Therapeutics Inc. (NASDAQ:DNLI) gained 17.6% to $19.87 following quarterly results.
    • National Vision Holdings, Inc. (NASDAQ:EYE) rose 17.6% to $23.48 following strong results.
    • Magnite, Inc. (NASDAQ:MGNI) rose 15.7% to $ 11.31.
    • Portillo's Inc. (NASDAQ:PTLO) gained 15.6% to $15.90 following upbeat results.
    • Dorman Products, Inc. (NASDAQ:DORM) climbed 11.5% to $92.67 following upbeat earnings.
    • Constellation Energy Corporation (NASDAQ:CEG) gained 9.7% to $146.27 following strong sales..
    • TransMedics Group, Inc. (NASDAQ:TMDX) gained 9.5% to $85.14 after the company reported better-than-expected fourth-quarter financial results and issued strong guidance.

     

    Now Read This: Top 3 Energy Stocks That Could Sink Your Portfolio In Q1

    Get the next $AHCO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AHCO
    $BBAI
    $BEAM
    $CEG

    CompanyDatePrice TargetRatingAnalyst
    Viking Therapeutics Inc.
    $VKTX
    3/26/2026Peer Perform
    Wolfe Research
    Denali Therapeutics Inc.
    $DNLI
    3/26/2026$32.00 → $42.00Buy
    H.C. Wainwright
    Constellation Energy Corporation
    $CEG
    3/25/2026$385.00Overweight
    Morgan Stanley
    Ligand Pharmaceuticals Incorporated
    $LGND
    3/11/2026$244.00Buy
    BofA Securities
    Hims & Hers Health Inc.
    $HIMS
    3/10/2026$24.00Sell → Neutral
    Citigroup
    Hims & Hers Health Inc.
    $HIMS
    3/10/2026$23.00Underperform → Neutral
    BofA Securities
    Hims & Hers Health Inc.
    $HIMS
    3/9/2026$30.00Hold → Buy
    Needham
    Portillo's Inc.
    $PTLO
    3/9/2026Peer Perform
    Wolfe Research
    More analyst ratings

    $AHCO
    $BBAI
    $BEAM
    $CEG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Goel Rajeev K.

    4 - PubMatic, Inc. (0001422930) (Issuer)

    4/3/26 6:28:18 PM ET
    $PUBM
    Computer Software: Programming Data Processing
    Technology

    SEC Form 4 filed by Woods Andrew

    4 - PubMatic, Inc. (0001422930) (Issuer)

    4/3/26 5:30:22 PM ET
    $PUBM
    Computer Software: Programming Data Processing
    Technology

    SEC Form 4 filed by Kumar Mukul

    4 - PubMatic, Inc. (0001422930) (Issuer)

    4/3/26 5:21:07 PM ET
    $PUBM
    Computer Software: Programming Data Processing
    Technology

    $AHCO
    $BBAI
    $BEAM
    $CEG
    SEC Filings

    View All

    Denali Therapeutics Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Denali Therapeutics Inc. (0001714899) (Filer)

    4/3/26 2:43:37 PM ET
    $DNLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEFA14A filed by Viking Therapeutics Inc.

    DEFA14A - Viking Therapeutics, Inc. (0001607678) (Filer)

    4/1/26 4:15:28 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Viking Therapeutics Inc.

    DEF 14A - Viking Therapeutics, Inc. (0001607678) (Filer)

    4/1/26 4:14:56 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHCO
    $BBAI
    $BEAM
    $CEG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lee Eugene I Jr bought $1,481,480 worth of shares (286,000 units at $5.18) (SEC Form 4)

    4 - Portillo's Inc. (0001871509) (Issuer)

    3/13/26 6:15:06 PM ET
    $PTLO
    Restaurants
    Consumer Discretionary

    Large owner Cashin Richard M Jr bought $19,912,148 worth of shares (2,046,691 units at $9.73) (SEC Form 4)

    4 - AdaptHealth Corp. (0001725255) (Issuer)

    3/12/26 9:11:41 PM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    Director Wolf Dale B bought $71,680 worth of shares (8,000 units at $8.96), increasing direct ownership by 8% to 104,235 units (SEC Form 4)

    4 - AdaptHealth Corp. (0001725255) (Issuer)

    3/3/26 6:41:28 PM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    $AHCO
    $BBAI
    $BEAM
    $CEG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Viking Therapeutics

    Wolfe Research initiated coverage of Viking Therapeutics with a rating of Peer Perform

    3/26/26 9:00:52 AM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright reiterated coverage on Denali Therapeutics with a new price target

    H.C. Wainwright reiterated coverage of Denali Therapeutics with a rating of Buy and set a new price target of $42.00 from $32.00 previously

    3/26/26 8:14:15 AM ET
    $DNLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Morgan Stanley resumed coverage on Constellation Energy with a new price target

    Morgan Stanley resumed coverage of Constellation Energy with a rating of Overweight and set a new price target of $385.00

    3/25/26 8:52:01 AM ET
    $CEG
    Electric Utilities: Central
    Utilities

    $AHCO
    $BBAI
    $BEAM
    $CEG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)

    Denali plans to continue clinical development of DNL593, which is designed to deliver progranulin to the brain using TransportVehicle™ technologyResults from ongoing Phase 1/2 study in patients with FTD-GRN expected by the end of 2026 SOUTH SAN FRANCISCO, Calif., April 03, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI) today announced that it has received notification from Takeda of its decision to terminate the collaboration agreement between the two companies to co-develop and co-commercialize DNL593 (PTV:PGRN). The decision was driven by strategic considerations and is not related to efficacy or safety data. DNL593 is an investigational progranulin replacement therapy

    4/3/26 1:30:00 PM ET
    $DNLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Quálitas Scales Agentic AI for End-to-End Claims Resolution With SoundHound AI's AI Agent Platform

    SANTA CLARA, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- SoundHound AI, Inc. (NASDAQ:SOUN), a global leader in voice and conversational AI, and Quálitas, a leading Mexican auto insurance company, today announced that the insurer has uplevelled its customer service operations by deploying SoundHound's agentic AI platform. The transition promises to deliver further gains in call containment, resolution efficiency, and improvements to the overall customer experience. Quálitas' adoption of agentic AI builds on a partnership that began in 2022, when the insurer first introduced the conversational AI platform to automate high-volume customer inquiries. Since then, SoundHound's AI-powered platf

    4/2/26 9:03:00 AM ET
    $SOUN
    Computer Software: Prepackaged Software
    Technology

    Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine

    Prestigious Publication Reinforces risto-cel's Durable, Differentiated Clinical Data for the Treatment of SCD with Severe Vaso-occlusive Crises (VOCs) Initially Presented at ASH, Data from 31 Patients with SCD Demonstrated Deep Resolution of Red Blood Cell Dysfunction and Reduced Time in Hospital Driven by a Median of One Cell Collection Cycle and Rapid Engraftment U.S. Biologics License Application (BLA) Submission for risto-cel Expected as Early as Year-End 2026 CAMBRIDGE, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the publication of data from

    4/1/26 5:12:19 PM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AHCO
    $BBAI
    $BEAM
    $CEG
    Leadership Updates

    Live Leadership Updates

    View All

    Norwegian Cruise Line Holdings Announces Board Refreshment

    Appoints Five New Independent Members to the BoardEnters into Cooperation Agreement with Elliott MIAMI, March 27, 2026 (GLOBE NEWSWIRE) -- Norwegian Cruise Line Holdings Ltd. (the "Company" or "NCLH") (NYSE:NCLH), a leading global cruise company operating Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises, today announced the appointment of five highly qualified members to its Board of Directors and a cooperation agreement reached with Elliott Investment Management L.P. (together with its affiliates, "Elliott"). The appointments reaffirm the Company's commitment to Board refreshment and shareholder value creation. Effective March 31, 2026, the following individuals wi

    3/27/26 8:30:00 AM ET
    $NCLH
    Marine Transportation
    Consumer Discretionary

    Independent Agencies Gain Advanced Agentic Media Buying Through New PubMatic and Untapped Growth Collective Partnership

    Small and Independent agencies can now activate custom buyer agents within AgenticOS – providing full access to data curation, premium inventory at scale, and GPU-supported infrastructure delivering more efficient and effective performance campaigns PubMatic (NASDAQ:PUBM), the leading AI-powered ad tech company delivering digital advertising performance, and Untapped Growth, a multibillion-dollar media buying collective built for independent agencies and mid-market advertisers, today announced a partnership that gives independent agencies direct integration into AgenticOS. Through this collaboration, member agencies in the Untapped Growth collective can now deploy proprietary buyer agents

    3/25/26 9:03:00 AM ET
    $PUBM
    Computer Software: Programming Data Processing
    Technology

    Portillo's Appoints Jennifer Pecoraro-Striepling as Chief Development Officer

    CHICAGO, March 16, 2026 (GLOBE NEWSWIRE) -- Portillo's (NASDAQ:PTLO), the fast-casual restaurant brand known for its menu of Chicago-style favorites and unmatched guest experience, today announced the appointment of Jennifer Pecoraro-Striepling as Chief Development Officer. In this role, Pecoraro-Striepling will lead Portillo's restaurant development strategy, including real estate and site selection, prototype design, and construction. She will play a key role in advancing Portillo's long-term expansion as the company continues to grow its footprint while preserving the brand's unique guest experience and operational excellence. "Jennifer brings the experience, strategic vision, and peo

    3/16/26 8:00:00 AM ET
    $PTLO
    Restaurants
    Consumer Discretionary

    $AHCO
    $BBAI
    $BEAM
    $CEG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by BigBear.ai Inc.

    SC 13D/A - BigBear.ai Holdings, Inc. (0001836981) (Subject)

    12/16/24 9:09:02 PM ET
    $BBAI
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13D/A filed by BigBear.ai Inc.

    SC 13D/A - BigBear.ai Holdings, Inc. (0001836981) (Subject)

    12/12/24 4:17:36 PM ET
    $BBAI
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13D/A filed by BigBear.ai Inc.

    SC 13D/A - BigBear.ai Holdings, Inc. (0001836981) (Subject)

    12/10/24 4:15:32 PM ET
    $BBAI
    Computer Software: Prepackaged Software
    Technology

    $AHCO
    $BBAI
    $BEAM
    $CEG
    Financials

    Live finance-specific insights

    View All

    Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)

    First new FDA-approved treatment option in nearly 20 years for families living with this rare lysosomal storage diseaseFirst FDA-approved medicine in emerging new class of biotherapeutics that leverage transferrin receptor to cross blood-brain barrierDenali's first medicine enabled by its TransportVehicle™ platform designed to deliver biotherapeutics to whole body, including brainRare Pediatric Disease Priority Review Voucher (PRV) awarded in connection with FDA approvalDenali to host conference call and webcast today at 12:30 p.m. Eastern time SOUTH SAN FRANCISCO, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI) today announced the U.S. Food and Drug Adm

    3/25/26 11:50:28 AM ET
    $DNLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development

    Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up Corrected M-AAT Comprised 94% of Total AAT with a Concomitant 84% Reduction in Mutant Z-AAT Following BEAM-302 60 mg Treatment Post-treatment Inducibility of AAT Observed During Respiratory Infection with a Patient Reaching ~30 µM Total AAT, Retaining 95% M-AAT Composition Well-tolerated Safety Profile Observed with Single Doses of BEAM-302 up to 75 mg; Safety Consistent Across Single-dose Part A and Part B Cohorts 60 mg Selected as Optimal Biological Dose, Supported by Strong Safety and E

    3/25/26 7:00:00 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    National Vision Holdings, Inc. Reports Fourth Quarter and Fiscal 2025 Financial Results

    2025 Results Mark a Year of Strong Momentum Fueled by Strategic Transformation, Cost Discipline Expansion Into Targeted Customer Cohorts Drove Enhanced Profitability, Positioning Company for Sustained Growth Provides 2026 Guidance Fourth quarter 2025 highlights compared to fourth quarter 2024*: Net revenue from continuing operations of $503.4 million, increased 15.1% Comparable store sales growth of 6.6% and Adjusted Comparable Store Sales Growth of 4.8%, represented 12 consecutive quarters of positive growth Net income from continuing operations of $3.3 million, Diluted EPS from continuing operations of $0.04, with Income (loss) from continuing operations margin improving to 0.7

    3/4/26 6:00:00 AM ET
    $EYE
    Ophthalmic Goods
    Health Care